Evidence map›Paper›PMID 35670478›Full record

ArticleAmerican journal of physiology. Lung cellular and molecular physiology2022

Impact of e-cigarette aerosol on primary human alveolar epithelial type 2 cells.

Katherine D Wick, Xiaohui Fang, Mazharul Maishan, Shotaro Matsumoto, Natasha Spottiswoode, Aartik Sarma, Camille Simoneau, Manisha Khakoo, Chaz Langelier, Carolyn S Calfee and 2 more

Open access · greenAbstract read
In one paragraph

Article in American journal of physiology. Lung cellular and molecular physiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. The triple-hit hypothesis: exploring pulmonary e-cigarette, PMEuropean respiratory review : an official journal of the European Respiratory Society · 2026
    Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. NAM journal · 2025
    Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Katherine D WickCardiovascular Research Institute, University of California, San Francisco, California.ORCID 0000-0001-9070-5490
Xiaohui FangCardiovascular Research Institute, University of California, San Francisco, California.
Mazharul MaishanCardiovascular Research Institute, University of California, San Francisco, California.ORCID 0000-0002-6374-7211
Shotaro MatsumotoCardiovascular Research Institute, University of California, San Francisco, California.
Natasha SpottiswoodeDivision of Infectious Diseases, Department of Medicine, University of California, San Francisco, California.
Aartik SarmaDivision of Pulmonary and Critical Care, Department of Medicine, University of California, San Francisco, California.
Camille SimoneauGladstone Institutes, University of California, San Francisco, California.
Manisha KhakooCardiovascular Research Institute, University of California, San Francisco, California.
Chaz LangelierDivision of Infectious Diseases, Department of Medicine, University of California, San Francisco, California.
Carolyn S CalfeeCardiovascular Research Institute, University of California, San Francisco, California.ORCID 0000-0001-9208-6865
Jeffrey E GottsCardiovascular Research Institute, University of California, San Francisco, California.ORCID 0000-0002-6269-8753
Michael A MatthayCardiovascular Research Institute, University of California, San Francisco, California.ORCID 0000-0003-3039-8155
University of California, San Francisco · USGladstone Institutes · US

Funding

PROJECT 5: IMPACT OF CHANGING TOBACCO PRODUCT USE ON HEALTHCARE COSTS FOR GENERAL AND VULNERABLE POPULATIONSU54HL147127 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JACOB, PEYTON · 2018 to 2022
$20.4M
NHLBI NIH HHS U54 HL147127
6 · The paper itself

Abstract

Electronic cigarettes (e-cigarettes) are designed to simulate combustible cigarette smoking and to aid in smoking cessation. Although the number of e-cigarette users has been increasing, the potential health impacts and biological effects of e-cigarettes are still not fully understood. Previous research has focused on the biological effects of e-cigarettes on lung cancer cell lines and distal airway epithelial cells; however, there have been few published studies on the effect of e-cigarettes on primary lung alveolar epithelial cells. The primary purpose of this study was to investigate the direct effect of e-cigarette aerosol on primary human lung alveolar epithelial type 2 (AT2) cells, both alone and in the presence of viral infection. The Melo-3 atomizer caused direct AT2 cell toxicity, whereas the more popular Juul pod's aerosol did not have a detectable cytotoxic effect on AT2 cells. Juul nicotine aerosol also did not increase short-term susceptibility to viral infection. However, 3 days of exposure upregulated genes central to the generation of reactive oxygen species, lipid peroxidation, and carcinogen metabolism and downregulated key innate immune system genes related to cytokine and chemokine signaling. These findings have implications for the potentially injurious impact of long-term use of popular low-power e-cigarette pods on the human alveolar epithelium. Gene expression data might be an important endpoint for evaluating the potential harmful effects of vaping devices that do not cause overt toxicity.

Indexed as

Electronic Nicotine Delivery SystemsVapingAlveolar Epithelial CellsHumansNicotineRespiratory Aerosols and DropletsNicotinealveolar type II cellse-cigarettesEVALIinflammationpulmonary edema

Identifiers

PMID35670478
PMCPMC9559034
OpenAlexW4281944355

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.